![]() |
| Tumor and peritoneal metastases are shown in yellow. Image Credit: UCR/Pellecchia lab |
Last year, researchers at the University of California, Riverside, developed a novel “molecular crowbar” strategy to degrade the oncogenic enzyme Pin1, a protein that is overexpressed in many tumors including pancreatic cancer. They designed compounds that bind to Pin1 and destabilize its structure, causing its cellular degradation.
This approach not only targets cancer cells directly but also addresses tumor-supporting cells like cancer-associated fibroblasts and macrophages where Pin1 is active, potentially overcoming the treatment resistance posed by the fibrous tumor microenvironment in pancreatic cancer.
The UCR team led by Maurizio Pellecchia, a distinguished professor of biomedical sciences in the School of Medicine, has now collaborated with a team of scientists led by Dr. Mustafa Raoof at City of Hope in Duarte, California, to further test these degraders in pancreatic and gastrointestinal cancers with the goal of developing a new class of therapeutics that can “remove” harmful proteins rather than just block them.
_1.jpg)

_MoreDetail-v3_x2_1352x762.jpg)



.jpg)
_MoreDetail-v3_x2_1480x986.jpg)



.jpg)

.jpg)
